首页 > 最新文献

Journal of Drug Assessment最新文献

英文 中文
Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews. 艾滋病毒感染者的治疗和合并症负担:系统文献综述。
IF 2.4 Pub Date : 2023-01-01 DOI: 10.1080/21556660.2022.2149963
Babafemi O Taiwo, Hela Romdhani, Marie-Hélène Lafeuille, Rhea Bhojwani, Katherine Milbers, Prina Donga

Background: As the human immunodeficiency virus (HIV) treatment landscape continues to evolve, the prolonged life expectancy and long-term exposure to antiretroviral drugs have modified the burden associated with living with HIV.

Objective: To better understand the current treatment and comorbidity burden in people living with HIV (PLWH).

Methods: Peer-reviewed systematic literature reviews (SLRs) between 2017 and 2020 that included US studies and examined drug adherence/pill burden, resistance burden, or comorbidities in PLWH were identified. Methods and findings were extracted for the overall studies and examined in the subset of US studies.

Results: Among 665 publications identified, 47 met the inclusion criteria (drug adherence/pill burden: 5; resistance: 3; comorbidities: 40). While antiretroviral drug adherence levels varied across SLRs, single-tablet regimens (STR) were associated with higher adherence versus multiple-tablet regimens. STRs were also associated with lower risk of treatment discontinuation, higher cost-effectiveness, and lower risk of hospitalization. Longer survival resulted in a high comorbidity burden, with non-AIDS causes accounting for 47% of deaths among PLWH in the US. HIV doubled the risk of cardiovascular disease and was associated with other health problems, including bone and muscle diseases, depression, and cancers. Several antiretroviral regimens were associated with chronic diseases, including cardiometabolic conditions. Lifetime HIV costs are substantially increasing, driven by antiretroviral, adverse event, and comorbidity treatment costs cumulated due to longer survival times.

Conclusions: There is a considerable burden associated with HIV and antiretroviral treatment, highlighting the benefits of less complex and safer regimens, and the unmet need for effective preventative interventions.

背景:随着人类免疫缺陷病毒(HIV)治疗领域的不断发展,预期寿命的延长和长期接触抗逆转录病毒药物已经改变了与艾滋病毒感染者相关的负担。目的:更好地了解HIV感染者(PLWH)的治疗现状和合并症负担。方法:2017年至2020年的同行评审系统文献综述(slr),包括美国的研究,并检查了PLWH的药物依从性/药丸负担、耐药负担或合并症。从总体研究中提取方法和结果,并在美国研究的子集中进行检验。结果:在665篇文献中,47篇符合纳入标准(药物依从性/药丸负担:5;阻力:3;并发症:40)。虽然抗逆转录病毒药物依从性水平在不同的slr中有所不同,但单片方案(STR)与多片方案相比具有更高的依从性。str还与较低的治疗中断风险、较高的成本效益和较低的住院风险相关。较长的生存期导致较高的合并症负担,非艾滋病原因占美国PLWH死亡的47%。艾滋病毒使患心血管疾病的风险增加了一倍,并与其他健康问题有关,包括骨骼和肌肉疾病、抑郁症和癌症。一些抗逆转录病毒疗法与慢性疾病有关,包括心脏代谢疾病。由于抗逆转录病毒治疗、不良事件和因生存时间延长而累积的合并症治疗费用,终生艾滋病毒感染成本正在大幅增加。结论:与艾滋病毒和抗逆转录病毒治疗相关的负担相当大,突出了不太复杂和更安全的方案的益处,以及对有效预防干预措施的未满足需求。
{"title":"Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews.","authors":"Babafemi O Taiwo,&nbsp;Hela Romdhani,&nbsp;Marie-Hélène Lafeuille,&nbsp;Rhea Bhojwani,&nbsp;Katherine Milbers,&nbsp;Prina Donga","doi":"10.1080/21556660.2022.2149963","DOIUrl":"https://doi.org/10.1080/21556660.2022.2149963","url":null,"abstract":"<p><strong>Background: </strong>As the human immunodeficiency virus (HIV) treatment landscape continues to evolve, the prolonged life expectancy and long-term exposure to antiretroviral drugs have modified the burden associated with living with HIV.</p><p><strong>Objective: </strong>To better understand the current treatment and comorbidity burden in people living with HIV (PLWH).</p><p><strong>Methods: </strong>Peer-reviewed systematic literature reviews (SLRs) between 2017 and 2020 that included US studies and examined drug adherence/pill burden, resistance burden, or comorbidities in PLWH were identified. Methods and findings were extracted for the overall studies and examined in the subset of US studies.</p><p><strong>Results: </strong>Among 665 publications identified, 47 met the inclusion criteria (drug adherence/pill burden: 5; resistance: 3; comorbidities: 40). While antiretroviral drug adherence levels varied across SLRs, single-tablet regimens (STR) were associated with higher adherence versus multiple-tablet regimens. STRs were also associated with lower risk of treatment discontinuation, higher cost-effectiveness, and lower risk of hospitalization. Longer survival resulted in a high comorbidity burden, with non-AIDS causes accounting for 47% of deaths among PLWH in the US. HIV doubled the risk of cardiovascular disease and was associated with other health problems, including bone and muscle diseases, depression, and cancers. Several antiretroviral regimens were associated with chronic diseases, including cardiometabolic conditions. Lifetime HIV costs are substantially increasing, driven by antiretroviral, adverse event, and comorbidity treatment costs cumulated due to longer survival times.</p><p><strong>Conclusions: </strong>There is a considerable burden associated with HIV and antiretroviral treatment, highlighting the benefits of less complex and safer regimens, and the unmet need for effective preventative interventions.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/3f/IJDA_12_2149963.PMC9793945.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10802752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses. 对欧盟和北非市场上可能不合格的干粉吸入器的调查——对输送剂量和细颗粒剂量的评估。
IF 2.4 Pub Date : 2022-09-28 eCollection Date: 2022-01-01 DOI: 10.1080/21556660.2022.2125727
Yue Zhang, Philippe Hubert, Cédric Hubert

Purpose: Discovery of falsified Symbicort 320/9 Turbohaler identified in the UK in 2013 demonstrated that falsified dry powder inhalers were also present in the European market. This work aimed to investigate the current situation of formoterol-containing dry powder inhalers in Europe and North Africa by assessing their aerodynamic performance profile.

Methods: A total of eight registered formoterol-based dry powder inhalers over the European and North African markets were involved in this study, including the reference drug Foradil. Samples were prepared using a multistage liquid impinger (MsLI) and further analyzed by a validated HPLC-UV method to determine the delivered and the fine particle doses (FPDs). This study also examined the impact of freezing-thawing cycles on sample stability in terms of analytical purpose handling.

Results: No substandard dry powder inhalers were identified among the medicinal products involved in this work. The delivered dose (DD) of assessed drugs varied from 8.33 to 9.69 µg, while the FPD was between 1.86 and 3.35 µg. As expected, this work confirmed that the capsule composition and the barrier properties of the primary packaging can affect the FPD of dry powder for inhalation use.

Conclusions: The FPD of products C and B was, respectively, 17.4 and 14.2% superior to Foradil, products D and H had the closest values compared to the original drug, and product F was 34.5% inferior. Additionally, this work showed that a high FPD can be achieved using HPMC capsules and moisture-impermeable primary packaging.

目的:2013年在英国发现伪造的辛比柯320/9涡轮增压器,这表明欧洲市场上也存在伪造的干粉吸入器。这项工作旨在通过评估其气动性能概况,调查欧洲和北非含福莫特罗干粉吸入器的现状。方法:本研究涉及欧洲和北非市场上注册的8种福摩特罗干粉吸入器,包括参比药福拉地尔。采用多级液体冲击器(MsLI)制备样品,并采用高效液相色谱-紫外(HPLC-UV)方法进行分析,以确定递送剂量和细颗粒剂量(fpd)。本研究还考察了冻融循环对样品稳定性分析目的处理方面的影响。结果:未发现不合格的干粉吸入器。给药剂量(DD)在8.33 ~ 9.69µg之间,FPD在1.86 ~ 3.35µg之间。正如预期的那样,这项工作证实了胶囊组成和初级包装的阻隔性能会影响吸入用干粉的FPD。结论:产品C和B的FPD分别比原药高17.4%和14.2%,产品D和H与原药最接近,产品F比原药低34.5%。此外,这项工作表明,使用HPMC胶囊和不透湿的初级包装可以实现高FPD。
{"title":"Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses.","authors":"Yue Zhang,&nbsp;Philippe Hubert,&nbsp;Cédric Hubert","doi":"10.1080/21556660.2022.2125727","DOIUrl":"https://doi.org/10.1080/21556660.2022.2125727","url":null,"abstract":"<p><strong>Purpose: </strong>Discovery of falsified Symbicort 320/9 Turbohaler identified in the UK in 2013 demonstrated that falsified dry powder inhalers were also present in the European market. This work aimed to investigate the current situation of formoterol-containing dry powder inhalers in Europe and North Africa by assessing their aerodynamic performance profile.</p><p><strong>Methods: </strong>A total of eight registered formoterol-based dry powder inhalers over the European and North African markets were involved in this study, including the reference drug Foradil. Samples were prepared using a multistage liquid impinger (MsLI) and further analyzed by a validated HPLC-UV method to determine the delivered and the fine particle doses (FPDs). This study also examined the impact of freezing-thawing cycles on sample stability in terms of analytical purpose handling.</p><p><strong>Results: </strong>No substandard dry powder inhalers were identified among the medicinal products involved in this work. The delivered dose (DD) of assessed drugs varied from 8.33 to 9.69 µg, while the FPD was between 1.86 and 3.35 µg. As expected, this work confirmed that the capsule composition and the barrier properties of the primary packaging can affect the FPD of dry powder for inhalation use.</p><p><strong>Conclusions: </strong>The FPD of products C and B was, respectively, 17.4 and 14.2% superior to Foradil, products D and H had the closest values compared to the original drug, and product F was 34.5% inferior. Additionally, this work showed that a high FPD can be achieved using HPMC capsules and moisture-impermeable primary packaging.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/d4/IJDA_11_2125727.PMC9543106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. 韩国HR+/HER2-局部晚期或转移性乳腺癌患者治疗模式和卫生资源利用的真实世界证据研究
IF 2.4 Pub Date : 2022-08-08 eCollection Date: 2022-01-01 DOI: 10.1080/21556660.2022.2107834
Diego Novick, Sae Young Lee, Dong Hyun Koo, Agota Szende, Sam Colman

Objective: To understand current treatment patterns and health care resource utilization (HRU) of women with locally advanced or metastatic breast cancer (advanced breast cancer; ABC) in Korea overall and within patients who had progressed with prior endocrine therapy (as first-line treatment for metastatic disease) and patients with no prior systemic treatment (for advanced disease).

Methods: A chart review was conducted in 109 patients (women ≥ 18 years old with HR+/HER2- ABC diagnosed between 2015 and 2017) from 11 hospitals. Anonymized data on patient characteristics, treatment patterns and HRU was abstracted.

Results: Mean (range) age of all patients was 57.5 (40-81) years. Overall, the most common first-, second- and third-line systemic therapy after diagnosis of ABC were letrozole ± palbociclib (51%), endocrine therapy (ET)±everolimus (42%) or chemotherapy (ChT) (39%), and ChT (68%), respectively. In patients progressed with ET (n = 33) and those with no prior systemic treatment (n = 52), the most common first-line treatments were letrozole (82%) and letrozole + palbociclib (42%), respectively. The percentage of patients with at least one grade 3 or higher adverse event during first-line therapy was 93.1% vs 39.2% in patients on a ChT based regimen (N = 29) vs. ET (N = 74). Overall, oncologist visits, at an annual rate of 9.27 (95% CI: 8.87, 9.69) visits per month, and hospitalizations, with an annual rate of 0.44 (95% CI: 0.36, 0.54), and mean (SD) length of stay of 14.3 (10.32) days, were the key drivers of HRU.

Conclusions: These findings on real world HRU reflected clinical guidelines and severity of ABC. Results can inform future evaluations of new ABC treatments that estimate the health economic impact of their adoption in Korea.

目的:了解局部晚期或转移性乳腺癌(晚期乳腺癌;ABC)在韩国总体和既往接受内分泌治疗(作为转移性疾病的一线治疗)和既往未接受全身治疗(晚期疾病)的患者中进行。方法:对来自11家医院的109例患者(2015年至2017年诊断为HR+/HER2- ABC的女性≥18岁)进行图表回顾。对患者特征、治疗模式和HRU的匿名数据进行了抽象。结果:所有患者的平均(范围)年龄为57.5岁(40-81岁)。总的来说,ABC诊断后最常见的一线、二线和三线全身治疗分别是来曲唑±帕博西尼(51%)、内分泌治疗(ET)±依维莫司(42%)或化疗(ChT)(39%)和ChT(68%)。在进展为ET的患者(n = 33)和未接受过全身治疗的患者(n = 52)中,最常见的一线治疗方法分别是来曲唑(82%)和来曲唑+帕博西尼(42%)。一线治疗期间至少发生一次3级或以上不良事件的患者比例为93.1%,而基于ChT方案(N = 29)和ET方案(N = 74)的患者比例为39.2%。总体而言,HRU的关键驱动因素是每月肿瘤医生的年访问率为9.27次(95% CI: 8.87, 9.69),住院率为0.44次(95% CI: 0.36, 0.54),平均(SD)住院时间为14.3(10.32)天。结论:这些真实世界HRU的发现反映了ABC的临床指南和严重程度。结果可以为今后评估新的ABC治疗方法提供信息,以估计在韩国采用这种治疗方法的健康经济影响。
{"title":"Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea.","authors":"Diego Novick,&nbsp;Sae Young Lee,&nbsp;Dong Hyun Koo,&nbsp;Agota Szende,&nbsp;Sam Colman","doi":"10.1080/21556660.2022.2107834","DOIUrl":"https://doi.org/10.1080/21556660.2022.2107834","url":null,"abstract":"<p><strong>Objective: </strong>To understand current treatment patterns and health care resource utilization (HRU) of women with locally advanced or metastatic breast cancer (advanced breast cancer; ABC) in Korea overall and within patients who had progressed with prior endocrine therapy (as first-line treatment for metastatic disease) and patients with no prior systemic treatment (for advanced disease).</p><p><strong>Methods: </strong>A chart review was conducted in 109 patients (women ≥ 18 years old with HR+/HER2- ABC diagnosed between 2015 and 2017) from 11 hospitals. Anonymized data on patient characteristics, treatment patterns and HRU was abstracted.</p><p><strong>Results: </strong>Mean (range) age of all patients was 57.5 (40-81) years. Overall, the most common first-, second- and third-line systemic therapy after diagnosis of ABC were letrozole ± palbociclib (51%), endocrine therapy (ET)±everolimus (42%) or chemotherapy (ChT) (39%), and ChT (68%), respectively. In patients progressed with ET (<i>n</i> = 33) and those with no prior systemic treatment (<i>n</i> = 52), the most common first-line treatments were letrozole (82%) and letrozole + palbociclib (42%), respectively. The percentage of patients with at least one grade 3 or higher adverse event during first-line therapy was 93.1% vs 39.2% in patients on a ChT based regimen (<i>N</i> = 29) vs. ET (<i>N</i> = 74). Overall, oncologist visits, at an annual rate of 9.27 (95% CI: 8.87, 9.69) visits per month, and hospitalizations, with an annual rate of 0.44 (95% CI: 0.36, 0.54), and mean (SD) length of stay of 14.3 (10.32) days, were the key drivers of HRU.</p><p><strong>Conclusions: </strong>These findings on real world HRU reflected clinical guidelines and severity of ABC. Results can inform future evaluations of new ABC treatments that estimate the health economic impact of their adoption in Korea.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/e3/IJDA_11_2107834.PMC9364702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40614649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen. 与CHOP化疗方案组成部分相关的长期后果风险综述。
IF 2.4 Pub Date : 2022-01-01 DOI: 10.1080/21556660.2022.2073101
Crystal Watson, Hemanth Gadikota, Arie Barlev, Rachel Beckerman

A common chemotherapy regimen in post-transplant lymphoproliferative disease (PTLD) following solid organ transplants (SOT) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). This study reviews the quantitative evidence for long-term consequences associated with components of CHOP identified from the Children's Oncology Group Long-Term Follow-Up Guidelines. Cited references were screened using prespecified criteria (English, systematic review, randomized controlled trial n > 100, observation study n > 100, case series n > 20). Relevant data were extracted and synthesized. Of 61 studies, 66% were retrospective cohort studies, 28% were in the US, and 95% enrolled pediatric patients. No study focused specifically on the CHOP regimen. Long-term consequences for CHOP components observed in >3 studies included cardiac toxicity (n = 14), hormone deficiencies/infertility (n = 14), secondary leukemia (n = 7), osteonecrosis (n = 6), and bladder cancer (n = 4). These effects are significant, impact a high percentage of patients, and occur as early as one year after treatment. Although none of the studies focused specifically on the CHOP regimen, 30%, 23%, and 15% evaluated alkylating agents (e.g. cyclophosphamide), anthracyclines (e.g. doxorubicin), and corticosteroids (e.g. prednisone), respectively. All three product classes had a dose-dependent risk of long-term consequences with up to 13.2-fold, 27-fold, 16-fold, 14.5-fold, and 6.2-fold increase in risk of heart failure, early menopause, secondary leukemia, bladder cancer, and osteonecrosis, respectively. Lymphoma patients had significantly elevated risks of cardiac toxicity (up to 12.2-fold), ovarian failure (up to 3.8-fold), and osteonecrosis (up to 6.7-fold). No studies were found in PTLD or SOT. Safe and effective PTLD treatments that potentially avoid these long-term consequences are urgently needed.

实体器官移植(SOT)后移植后淋巴细胞增生性疾病(PTLD)的常见化疗方案是环磷酰胺、阿霉素、长春新碱和泼尼松(CHOP)。本研究回顾了儿童肿瘤组长期随访指南中确定的CHOP成分相关长期后果的定量证据。采用预先设定的标准筛选被引文献(英文、系统综述、随机对照试验n > 100、观察研究n > 100、病例系列n > 20)。提取并综合相关数据。在61项研究中,66%为回顾性队列研究,28%在美国,95%纳入儿科患者。没有专门针对CHOP方案的研究。在超过3项研究中观察到CHOP成分的长期后果包括心脏毒性(n = 14)、激素缺乏/不育(n = 14)、继发性白血病(n = 7)、骨坏死(n = 6)和膀胱癌(n = 4)。这些影响是显著的,影响很大比例的患者,并且早在治疗一年后就会发生。虽然没有一项研究专门关注CHOP方案,但分别有30%、23%和15%的研究评估了烷基化剂(如环磷酰胺)、蒽环类药物(如阿霉素)和皮质类固醇(如强尼松)。所有三种产品类别都具有剂量依赖性的长期后果风险,心力衰竭、早期绝经、继发性白血病、膀胱癌和骨坏死的风险分别增加13.2倍、27倍、16倍、14.5倍和6.2倍。淋巴瘤患者发生心脏毒性(高达12.2倍)、卵巢功能衰竭(高达3.8倍)和骨坏死(高达6.7倍)的风险显著升高。未发现PTLD或SOT的相关研究。迫切需要安全有效的PTLD治疗,以潜在地避免这些长期后果。
{"title":"A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen.","authors":"Crystal Watson,&nbsp;Hemanth Gadikota,&nbsp;Arie Barlev,&nbsp;Rachel Beckerman","doi":"10.1080/21556660.2022.2073101","DOIUrl":"https://doi.org/10.1080/21556660.2022.2073101","url":null,"abstract":"<p><p>A common chemotherapy regimen in post-transplant lymphoproliferative disease (PTLD) following solid organ transplants (SOT) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). This study reviews the quantitative evidence for long-term consequences associated with components of CHOP identified from the Children's Oncology Group Long-Term Follow-Up Guidelines. Cited references were screened using prespecified criteria (English, systematic review, randomized controlled trial <i>n</i> > 100, observation study <i>n</i> > 100, case series <i>n</i> > 20). Relevant data were extracted and synthesized. Of 61 studies, 66% were retrospective cohort studies, 28% were in the US, and 95% enrolled pediatric patients. No study focused specifically on the CHOP regimen. Long-term consequences for CHOP components observed in >3 studies included cardiac toxicity (<i>n</i> = 14), hormone deficiencies/infertility (<i>n</i> = 14), secondary leukemia (<i>n</i> = 7), osteonecrosis (<i>n</i> = 6), and bladder cancer (<i>n</i> = 4). These effects are significant, impact a high percentage of patients, and occur as early as one year after treatment. Although none of the studies focused specifically on the CHOP regimen, 30%, 23%, and 15% evaluated alkylating agents (e.g. cyclophosphamide), anthracyclines (e.g. doxorubicin), and corticosteroids (e.g. prednisone), respectively. All three product classes had a dose-dependent risk of long-term consequences with up to 13.2-fold, 27-fold, 16-fold, 14.5-fold, and 6.2-fold increase in risk of heart failure, early menopause, secondary leukemia, bladder cancer, and osteonecrosis, respectively. Lymphoma patients had significantly elevated risks of cardiac toxicity (up to 12.2-fold), ovarian failure (up to 3.8-fold), and osteonecrosis (up to 6.7-fold). No studies were found in PTLD or SOT. Safe and effective PTLD treatments that potentially avoid these long-term consequences are urgently needed.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/97/IJDA_11_2073101.PMC9176678.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Real-world experience of ocrelizumab in multiple sclerosis in an Arab population. ocrelizumab治疗阿拉伯人群多发性硬化症的实际经验。
IF 2.4 Pub Date : 2021-10-19 eCollection Date: 2021-01-01 DOI: 10.1080/21556660.2021.1989193
Beatriz Garcia-Cañibano, Sami Ouanes, Gowrii Saswathy Ganesan, Wajiha Yousuf, Basel Humos, Tehniyat Baig, Faiza Ibrahim, Rajvir Singh, Dirk Deleu

Objective: Pivotal clinical trials revealed good clinical efficiency of ocrelizumab while having a good safety profile in the management of multiple sclerosis (MS). However, real-world data of ocrelizumab in daily clinical practice remain scarce. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for MS in an Arab population in a real-world clinical setting.

Methods: In this retrospective single-center observational study in Qatar, we reviewed the medical records and analyzed the clinical and MRI data of all patients with relapsing-remitting MS (RRMS) and active secondary progressive MS (aSPMS)-between October 2017 through December 2020-who had received at least one infusion of ocrelizumab (Q-OCRE).

Results: A total of 60 MS patients were included (57 with RRMS, three SPMS). The Median follow-up period was 19 months (range, 1-32). The most common reason for switching to ocrelizumab was increased disease activity and three-quarters of the patients were on a previous disease-modifying drug (DMD). No evidence of disease activity (NEDA) status at year 1 was achieved in 73% of the cohort. Mild infusion-related reactions (IRR) and infections were reported (mainly upper respiratory tract infections followed by urinary tract infection) with a declining percentage over the follow-up applications. No severe side effects were observed.

Conclusion: Our real-world experience confirms good efficacy, tolerability, and safety of ocrelizumab in our Arab population.

目的:关键临床试验显示ocrelizumab在治疗多发性硬化症(MS)中具有良好的临床疗效,同时具有良好的安全性。然而,ocrelizumab在日常临床实践中的实际数据仍然很少。本研究的目的是在现实世界的临床环境中评估ocrelizumab治疗阿拉伯人群多发性硬化症的初步安全性和有效性。方法:在卡塔尔的这项回顾性单中心观察性研究中,我们回顾了2017年10月至2020年12月期间接受至少一次ocrelizumab (Q-OCRE)输注的所有复发-缓解型MS (RRMS)和活动性继发性进展型MS (aSPMS)患者的医疗记录,并分析了临床和MRI数据。结果:共纳入60例MS患者(57例为RRMS, 3例为SPMS)。中位随访期为19个月(范围1-32)。切换到ocrelizumab的最常见原因是疾病活动性增加,并且四分之三的患者先前使用过疾病改善药物(DMD)。73%的队列在第1年没有达到疾病活动(NEDA)状态的证据。有轻度输液相关反应(IRR)和感染的报告(主要是上呼吸道感染,其次是尿路感染),在随访应用中百分比下降。没有观察到严重的副作用。结论:我们的实际经验证实了ocrelizumab在阿拉伯人群中的良好疗效、耐受性和安全性。
{"title":"Real-world experience of ocrelizumab in multiple sclerosis in an Arab population.","authors":"Beatriz Garcia-Cañibano,&nbsp;Sami Ouanes,&nbsp;Gowrii Saswathy Ganesan,&nbsp;Wajiha Yousuf,&nbsp;Basel Humos,&nbsp;Tehniyat Baig,&nbsp;Faiza Ibrahim,&nbsp;Rajvir Singh,&nbsp;Dirk Deleu","doi":"10.1080/21556660.2021.1989193","DOIUrl":"https://doi.org/10.1080/21556660.2021.1989193","url":null,"abstract":"<p><strong>Objective: </strong>Pivotal clinical trials revealed good clinical efficiency of ocrelizumab while having a good safety profile in the management of multiple sclerosis (MS). However, real-world data of ocrelizumab in daily clinical practice remain scarce. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for MS in an Arab population in a real-world clinical setting.</p><p><strong>Methods: </strong>In this retrospective single-center observational study in Qatar, we reviewed the medical records and analyzed the clinical and MRI data of all patients with relapsing-remitting MS (RRMS) and active secondary progressive MS (aSPMS)-between October 2017 through December 2020-who had received at least one infusion of ocrelizumab (Q-OCRE).</p><p><strong>Results: </strong>A total of 60 MS patients were included (57 with RRMS, three SPMS). The Median follow-up period was 19 months (range, 1-32). The most common reason for switching to ocrelizumab was increased disease activity and three-quarters of the patients were on a previous disease-modifying drug (DMD). No evidence of disease activity (NEDA) status at year 1 was achieved in 73% of the cohort. Mild infusion-related reactions (IRR) and infections were reported (mainly upper respiratory tract infections followed by urinary tract infection) with a declining percentage over the follow-up applications. No severe side effects were observed.</p><p><strong>Conclusion: </strong>Our real-world experience confirms good efficacy, tolerability, and safety of ocrelizumab in our Arab population.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/70/IJDA_10_1989193.PMC8530478.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39555897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis. Denosumab改善糖耐量受损患者的葡萄糖参数:一项系统回顾和荟萃分析。
IF 2.4 Pub Date : 2021-10-06 eCollection Date: 2021-01-01 DOI: 10.1080/21556660.2021.1989194
Blanca T Pacheco-Soto, Rebeca Garazi Elguezabal-Rodelo, Leonardo M Porchia, Enrique Torres-Rasgado, Ricardo Pérez-Fuentes, M Elba Gonzalez-Mejia

Objective: Receptor activator of NF-κβ ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI).

Methods: A systematic review was conducted to evaluate the effects of Denosumab on glycemic parameters. PubMed, SCOPUS, EBSCO, and LILACS databases were searched for studies that investigated the effect of Denosumab on FPG, glycated hemoglobin (HbA1c), FPI, and Homeostatic Model Assessment for Insulin Resistance (HOMA1-IR). The pooled standard difference in means (SDM) and 95% confidence intervals (95%CI) were calculated. The results were stratified into (1) Normal Glucose Tolerance (NGT) and (2) Impaired Glucose Tolerance (IGT).

Results: Six publications (1203 participants) were included. There was a significant association between Denosumab and FPG (SDM = -0.388, 95%CI: -0.705 to -0.070, p = .017) and with HOMA1-IR (SDM = -0.223, 95%CI: -0.388 to -0.058, p = .008), but not for HbA1c and FPI. When stratified by glucose tolerance, the association between Denosumab and FPG, HbA1c, and HOMA1-IR was present for the IGT group. Lastly, Denosumab had a time-dependent effect on HbA1c (slope = -0.037, 95%CI: -0.059 to -0.015, p < .005).

Conclusions: Denosumab significantly improved glycemic parameters. This outcome was more prominent for subjects with compromised glucose tolerance, positing that Denosumab can be used as a treatment to improve glucose metabolism for persons with pre-diabetes and diabetes.

目的:NF-κβ配体受体激活因子(Receptor activator of NF-κβ ligand, RANKL)在肝脏胰岛素抵抗和葡萄糖摄取不良的发生中起重要作用;因此,用Denosumab抑制RANKL可以改善空腹血糖(FPG)和胰岛素(FPI)。方法:系统评价Denosumab对血糖指标的影响。检索PubMed、SCOPUS、EBSCO和LILACS数据库,研究Denosumab对FPG、糖化血红蛋白(HbA1c)、FPI和胰岛素抵抗稳态模型评估(HOMA1-IR)的影响。计算汇总均数标准差(SDM)和95%置信区间(95% ci)。结果分为(1)糖耐量正常(NGT)和(2)糖耐量受损(IGT)。结果:纳入6篇文献(1203名受试者)。Denosumab与FPG (SDM = -0.388, 95%CI: -0.705至-0.070,p = 0.017)和hom_1 - ir (SDM = -0.223, 95%CI: -0.388至-0.058,p = 0.008)有显著相关性,但与HbA1c和FPI无显著相关性。当按葡萄糖耐量分层时,在IGT组中,Denosumab与FPG、HbA1c和HOMA1-IR存在关联。最后,Denosumab对HbA1c具有时间依赖性(斜率= -0.037,95%CI: -0.059至-0.015,p)。结论:Denosumab显著改善血糖参数。对于糖耐量受损的受试者,这一结果更为突出,这表明Denosumab可用于改善糖尿病前期和糖尿病患者的糖代谢。
{"title":"Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis.","authors":"Blanca T Pacheco-Soto,&nbsp;Rebeca Garazi Elguezabal-Rodelo,&nbsp;Leonardo M Porchia,&nbsp;Enrique Torres-Rasgado,&nbsp;Ricardo Pérez-Fuentes,&nbsp;M Elba Gonzalez-Mejia","doi":"10.1080/21556660.2021.1989194","DOIUrl":"https://doi.org/10.1080/21556660.2021.1989194","url":null,"abstract":"<p><strong>Objective: </strong>Receptor activator of NF-κβ ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI).</p><p><strong>Methods: </strong>A systematic review was conducted to evaluate the effects of Denosumab on glycemic parameters. PubMed, SCOPUS, EBSCO, and LILACS databases were searched for studies that investigated the effect of Denosumab on FPG, glycated hemoglobin (HbA1c), FPI, and Homeostatic Model Assessment for Insulin Resistance (HOMA1-IR). The pooled standard difference in means (SDM) and 95% confidence intervals (95%CI) were calculated. The results were stratified into (1) Normal Glucose Tolerance (NGT) and (2) Impaired Glucose Tolerance (IGT).</p><p><strong>Results: </strong>Six publications (1203 participants) were included. There was a significant association between Denosumab and FPG (SDM = -0.388, 95%CI: -0.705 to -0.070, <i>p</i> = .017) and with HOMA1-IR (SDM = -0.223, 95%CI: -0.388 to -0.058, <i>p</i> = .008), but not for HbA1c and FPI. When stratified by glucose tolerance, the association between Denosumab and FPG, HbA1c, and HOMA1-IR was present for the IGT group. Lastly, Denosumab had a time-dependent effect on HbA1c (slope = -0.037, 95%CI: -0.059 to -0.015, <i>p</i> < .005).</p><p><strong>Conclusions: </strong>Denosumab significantly improved glycemic parameters. This outcome was more prominent for subjects with compromised glucose tolerance, positing that Denosumab can be used as a treatment to improve glucose metabolism for persons with pre-diabetes and diabetes.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2021-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/fb/IJDA_10_1989194.PMC8525927.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39564782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
2021 National Association of Specialty Pharmacy: Research Presentation Abstracts 2021年全国专业药学协会:研究报告摘要
IF 2.4 Pub Date : 2021-09-17 DOI: 10.1080/21556660.2021.1966231
Sheila Arquette, Jonathan Ogurchak, R. Brook
The National Association of Specialty Pharmacy (NASP) was scheduled to hold its 2021 Annual Meeting & Expo September 27–30, 2021;however, due to the ongoing COVID-19 pandemic, and out of concern for attendees, their families, their communities, and our front-line healthcare providers ,the conference was unfortunately cancelled. This year’s and poster presentation program provides an interactive forum to showcase research related to specialty pharmacy products and services. Many of this year’s s and posters focus on accomplishments, outcomes, and lessons learned as a result of COVID-19.
全国专业药学协会(NASP)计划于2021年9月27日至30日举行2021年会和博览会;然而,由于持续的新冠肺炎大流行,出于对与会者、他们的家人、他们的社区和我们的一线医疗保健提供者的担忧,会议不幸被取消。今年的和海报展示计划提供了一个互动论坛,展示与特色药房产品和服务相关的研究。今年的许多海报和海报都聚焦于新冠肺炎带来的成就、成果和教训。
{"title":"2021 National Association of Specialty Pharmacy: Research Presentation Abstracts","authors":"Sheila Arquette, Jonathan Ogurchak, R. Brook","doi":"10.1080/21556660.2021.1966231","DOIUrl":"https://doi.org/10.1080/21556660.2021.1966231","url":null,"abstract":"The National Association of Specialty Pharmacy (NASP) was scheduled to hold its 2021 Annual Meeting & Expo September 27–30, 2021;however, due to the ongoing COVID-19 pandemic, and out of concern for attendees, their families, their communities, and our front-line healthcare providers ,the conference was unfortunately cancelled. This year’s and poster presentation program provides an interactive forum to showcase research related to specialty pharmacy products and services. Many of this year’s s and posters focus on accomplishments, outcomes, and lessons learned as a result of COVID-19.","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48094571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the Ninth Annual National Association of Specialty Pharmacy (NASP) Meeting 第九届全国专业药学协会(NASP)年会摘要
IF 2.4 Pub Date : 2021-09-17 DOI: 10.1080/21556660.2021.1967594
{"title":"Abstracts from the Ninth Annual National Association of Specialty Pharmacy (NASP) Meeting","authors":"","doi":"10.1080/21556660.2021.1967594","DOIUrl":"https://doi.org/10.1080/21556660.2021.1967594","url":null,"abstract":"","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48852346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma. 替马洛尔-多唑胺固定联合治疗新诊断开角型青光眼的疗效和安全性:每日3次vs每日2次。
IF 2.4 Pub Date : 2021-08-23 eCollection Date: 2021-01-01 DOI: 10.1080/21556660.2021.1967642
Mohammad Pakravan, Afsaneh Naderi Beni, Shahin Yazdani, Hamed Esfandiari, Shahram Mirshojaee

Objective: This study aimed to compare the therapeutic efficacy and safety of dorzolamide/timolol fixed-combination(Cosopt) in newly diagnosed primary open-angle glaucoma (POAG) patients.

Methods: In this prospective, interventional case series, newly POAG patients were included. Patients were started on Cosopt twice a day (BID) for one month and then switched to three times a day (TDS) for an additional month. Patients underwent comprehensive ophthalmic examination, diurnal intraocular pressure (IOP), blood pressure (BP), and 24-h heart rate (HR) measurements at baseline, month 1(BID), and month 2(TDS). Throughout the study, all adverse events were monitored by the investigators.

Results: In 31 POAG patients that completed the study, the mean baseline IOP was 23.1 ± 3.15 mmHg. IOP was decreased significantly 16.5 ± 2.21 at one month (p < .0001) and 13.9 ± 2.23 mmHg at 1 and 2 months follow up (p < .0001). IOP was significantly lower in month 2 compared to month 1 (p = .0004). While Cosopt BID significantly reduced the mean 24-h systolic BP and mean 24-h HR from baseline (p < .0001), the mean 24-h systolic BP and HR remained unchanged with Cosopt TDS compared to BID (p = .62).

Conclusions: Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profiles.

目的:比较多唑胺/替洛尔固定联合治疗新发原发性开角型青光眼(POAG)的疗效和安全性。方法:在这个前瞻性的介入病例系列中,纳入了新发POAG患者。患者开始服用coopt,每天两次(BID),持续一个月,然后改为每天三次(TDS),再持续一个月。患者在基线、第1个月(BID)和第2个月(TDS)时接受全面眼科检查、每日眼压(IOP)、血压(BP)和24小时心率(HR)测量。在整个研究过程中,研究人员对所有不良事件进行了监测。结果:31例POAG患者完成研究,平均基线IOP为23.1±3.15 mmHg。1个月时IOP显著降低(16.5±2.21)(p p p = 0.0004)。而coopt BID较基线显著降低了平均24小时收缩压和平均24小时HR (p p = 0.62)。结论:在安全性相当的POAG患者中,coopt TDS比coopt BID具有更好的降低眼压的效果。
{"title":"Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma.","authors":"Mohammad Pakravan,&nbsp;Afsaneh Naderi Beni,&nbsp;Shahin Yazdani,&nbsp;Hamed Esfandiari,&nbsp;Shahram Mirshojaee","doi":"10.1080/21556660.2021.1967642","DOIUrl":"https://doi.org/10.1080/21556660.2021.1967642","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the therapeutic efficacy and safety of dorzolamide/timolol fixed-combination(Cosopt) in newly diagnosed primary open-angle glaucoma (POAG) patients.</p><p><strong>Methods: </strong>In this prospective, interventional case series, newly POAG patients were included. Patients were started on Cosopt twice a day (BID) for one month and then switched to three times a day (TDS) for an additional month. Patients underwent comprehensive ophthalmic examination, diurnal intraocular pressure (IOP), blood pressure (BP), and 24-h heart rate (HR) measurements at baseline, month 1(BID), and month 2(TDS). Throughout the study, all adverse events were monitored by the investigators.</p><p><strong>Results: </strong>In 31 POAG patients that completed the study, the mean baseline IOP was 23.1 ± 3.15 mmHg. IOP was decreased significantly 16.5 ± 2.21 at one month (<i>p</i> < .0001) and 13.9 ± 2.23 mmHg at 1 and 2 months follow up (<i>p</i> < .0001). IOP was significantly lower in month 2 compared to month 1 (<i>p</i> = .0004). While Cosopt BID significantly reduced the mean 24-h systolic BP and mean 24-h HR from baseline (<i>p</i> < .0001), the mean 24-h systolic BP and HR remained unchanged with Cosopt TDS compared to BID (<i>p</i> = .62).</p><p><strong>Conclusions: </strong>Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profiles.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2021-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/bd/IJDA_10_1967642.PMC8386705.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39357160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Seizure clusters. 癫痫集群。
IF 2.4 Pub Date : 2021-08-14 eCollection Date: 2021-01-01 DOI: 10.1080/21556660.2021.1962671
Boulenouar Mesraoua, Bassel Abou-Khalil, Rola Hosni Khodair, Gayane Melikyan, Hassan Al Hail, Ali A Asadi-Pooya

Acute repetitive seizures, also called seizure clusters, are common phenomena in patients with epilepsy. They are a burden on patients and their caregivers and may be very disruptive to the patients' lives. They may progress to prolonged seizures or status epilepticus if they are not aborted as soon as possible. However, their definition, recognition, and classification still suffer from a lack of consensus among healthcare professionals in the field. This review aims to shed light on various aspects of seizure clusters with particular attention to their treatments.

急性反复发作,又称发作群,是癫痫患者的常见现象。它们是患者和护理人员的负担,可能对患者的生活造成严重破坏。如果不尽快流产,可能会发展为长时间的癫痫发作或癫痫持续状态。然而,它们的定义、识别和分类仍然受到该领域医疗保健专业人员缺乏共识的影响。这篇综述的目的是阐明癫痫发作集群的各个方面,特别注意他们的治疗。
{"title":"Seizure clusters.","authors":"Boulenouar Mesraoua,&nbsp;Bassel Abou-Khalil,&nbsp;Rola Hosni Khodair,&nbsp;Gayane Melikyan,&nbsp;Hassan Al Hail,&nbsp;Ali A Asadi-Pooya","doi":"10.1080/21556660.2021.1962671","DOIUrl":"https://doi.org/10.1080/21556660.2021.1962671","url":null,"abstract":"<p><p>Acute repetitive seizures, also called seizure clusters, are common phenomena in patients with epilepsy. They are a burden on patients and their caregivers and may be very disruptive to the patients' lives. They may progress to prolonged seizures or status epilepticus if they are not aborted as soon as possible. However, their definition, recognition, and classification still suffer from a lack of consensus among healthcare professionals in the field. This review aims to shed light on various aspects of seizure clusters with particular attention to their treatments.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2021-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21556660.2021.1962671","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
期刊
Journal of Drug Assessment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1